person · Reporting owner

Rickey James Paul

Disclosed activity across 2 companies

Tapewire entity: 25347
SEC CIK: 0001606243

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Braveheart Bio, Inc.BRVE · Entity 4564	Chief Financial Officer	August 05, 2026	August 07, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Braveheart Bio, Inc.

Report date August 05, 2026 · Filed August 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	520,927	Reported balance After 2026-08-07 transaction · row 1 1 source row Row 1 · 2026-08-07 · Purchase · Acquired 27,777 · Balance 520,927
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-08-04	Direct	300,000	Reported balance After 2026-08-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-08-05 · Grant · Acquired 300,000 · Balance 300,000 F2: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Common StockSEC Table I · non-derivative	IndirectBy Rickey Trust CR	91,324	Reported balance Holding disclosure · report date 2026-08-05 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 91,324 F1: The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Rickey Trust BR	91,324	Reported balance Holding disclosure · report date 2026-08-05 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 91,324 F1: The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.

F2: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALPINE IMMUNE SCIENCES, INC.

Report date May 20, 2024 · Filed May 21, 2024

Section 16 reporting ended · disclosed 2024-05-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	31,200	Reported balance After 2024-05-20 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2024-05-20 · Disposition to issuer · Disposed 26,761 · Balance 31,200 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F3: Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-05-20 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2024-05-20 · Disposition to issuer · Disposed 31,200 · Balance 0 F3: Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F4: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each restricted stock unit of the Company (a Company RSU) that was then outstanding but not then vested became immediately vested in full. At the Effective Time, each Company RSU was automatically cancelled and the holder thereof became entitled to receive an amount in cash, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the number of shares of Common Stock underlying such Company RSU by (ii) the Merger Consideration.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.31 · Expires 2028-01-01	Direct	0	Reported balance After 2024-05-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-05-20 · Disposition to issuer · Disposed 836 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.02 · Expires 2027-04-11	Direct	0	Reported balance After 2024-05-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-05-20 · Disposition to issuer · Disposed 137 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.51 · Expires 2029-02-05	Direct	0	Reported balance After 2024-05-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-05-20 · Disposition to issuer · Disposed 143 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.23 · Expires 2030-01-22	Direct	0	Reported balance After 2024-05-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-05-20 · Disposition to issuer · Disposed 1,214 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.20 · Expires 2031-01-04	Direct	0	Reported balance After 2024-05-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-05-20 · Disposition to issuer · Disposed 112,945 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F9: One-fourth (1/4th) of the Shares subject to the Option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2032-01-03	Direct	0	Reported balance After 2024-05-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-05-20 · Disposition to issuer · Disposed 112,500 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F10: One-fourth (1/4) of the shares subject to the option will vest on January 4, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.55 · Expires 2033-01-03	Direct	0	Reported balance After 2024-05-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-05-20 · Disposition to issuer · Disposed 108,999 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F11: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.33 · Expires 2034-01-03	Direct	0	Reported balance After 2024-05-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-05-20 · Disposition to issuer · Disposed 78,000 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F12: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

F2: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.

F3: Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date.

F4: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each restricted stock unit of the Company (a Company RSU) that was then outstanding but not then vested became immediately vested in full. At the Effective Time, each Company RSU was automatically cancelled and the holder thereof became entitled to receive an amount in cash, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the number of shares of Common Stock underlying such Company RSU by (ii) the Merger Consideration.

F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.

F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.

F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof.

F9: One-fourth (1/4th) of the Shares subject to the Option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.

F10: One-fourth (1/4) of the shares subject to the option will vest on January 4, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.

F11: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.

F12: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 05, 2023 Filed Dec 7, 2023 00:31 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Exercise / conversionStock Option (Right to buy) · Derivative	418	$0.00 Strike: $3.23	$0.00	Disclosure SEC source: 0001626199-23-000128 · wk-form4_1701909064.xml · derivative · entry 8 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,946 Underlying: Common Stock · 418 shares Expires 2030-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document
December 05, 2023 Filed Dec 7, 2023 00:31 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	SaleCommon Stock	418	$16.01	$6,693.81	Disclosure SEC source: 0001626199-23-000128 · wk-form4_1701909064.xml · nonDerivative · entry 4 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 05, 2023 Filed Dec 7, 2023 00:31 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Exercise / conversionCommon Stock	418	$3.23	$1,350.14	Disclosure SEC source: 0001626199-23-000128 · wk-form4_1701909064.xml · nonDerivative · entry 3 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. Read SEC document
December 04, 2023 Filed Dec 7, 2023 00:31 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Exercise / conversionStock Option (Right to buy) · Derivative	63,947	$0.00 Strike: $3.23	$0.00	Disclosure SEC source: 0001626199-23-000128 · wk-form4_1701909064.xml · derivative · entry 7 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,364 Underlying: Common Stock · 63,947 shares Expires 2030-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document
December 04, 2023 Filed Dec 7, 2023 00:31 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	SaleCommon Stock	63,947	$16.06	$1,026,886.50	Disclosure SEC source: 0001626199-23-000128 · wk-form4_1701909064.xml · nonDerivative · entry 2 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 04, 2023 Filed Dec 7, 2023 00:31 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Exercise / conversionCommon Stock	63,947	$3.23	$206,548.81	Disclosure SEC source: 0001626199-23-000128 · wk-form4_1701909064.xml · nonDerivative · entry 1 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. Read SEC document
November 30, 2023 Filed Dec 1, 2023 22:00 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Exercise / conversionStock Option (Right to buy) · Derivative	700	$0.00 Strike: $3.23	$0.00	Disclosure SEC source: 0001606243-23-000003 · wk-form4_1701468033.xml · derivative · entry 3 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,311 Underlying: Common Stock · 700 shares Expires 2030-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document
November 30, 2023 Filed Dec 1, 2023 22:00 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	SaleCommon Stock	700	$16.00	$11,200.00	Disclosure SEC source: 0001606243-23-000003 · wk-form4_1701468033.xml · nonDerivative · entry 2 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. Read SEC document
November 30, 2023 Filed Dec 1, 2023 22:00 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Exercise / conversionCommon Stock	700	$3.23	$2,261.00	Disclosure SEC source: 0001606243-23-000003 · wk-form4_1701468033.xml · nonDerivative · entry 1 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. Read SEC document
November 06, 2023 Filed Nov 8, 2023 22:20 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Exercise / conversionStock Option (Right to buy) · Derivative	10,989	$0.00 Strike: $3.23	$0.00	Disclosure SEC source: 0001626199-23-000119 · wk-form4_1699482039.xml · derivative · entry 3 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,011 Underlying: Common Stock · 10,989 shares Expires 2030-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document
November 06, 2023 Filed Nov 8, 2023 22:20 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	SaleCommon Stock	18,003	$16.03	$288,553.88	Disclosure SEC source: 0001626199-23-000119 · wk-form4_1699482039.xml · nonDerivative · entry 2 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 06, 2023 Filed Nov 8, 2023 22:20 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Exercise / conversionCommon Stock	10,989	$3.23	$35,494.47	Disclosure SEC source: 0001626199-23-000119 · wk-form4_1699482039.xml · nonDerivative · entry 1 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023. Read SEC document
January 04, 2023 Filed Jan 6, 2023 00:01 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantStock Option (Right to buy) · Derivative	109,000	$0.00 Strike: $7.55	$0.00	Disclosure SEC source: 0001626199-23-000022 · wf-form4_167296329686813.xml · derivative · entry 1 Rickey James Paul · CIK 0001606243 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,000 Underlying: Common Stock · 109,000 shares Expires 2033-01-03 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document
January 04, 2022 Filed Jan 6, 2022 23:02 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantStock Option (Right to buy) · Derivative	112,500	$0.00 Strike: $13.30	$0.00	Disclosure SEC source: 0001626199-22-000023 · wf-form4_164151011836992.xml · derivative · entry 1 Rickey James Paul · CIK 0001606243 · Senior VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2032-01-03 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: One-fourth (1/4th) of the Shares subject to the Option will vest on the one (1)-year anniversary of January 4, 2022 (the "Vesting Commencement Date"), and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, such that 100% of the Shares subject to the Option will be vested and exercisable as of the four (4)-year anniversary of the Vesting Commencement Date, subject to Optionee continuing to be a Service Provider through each such date. Read SEC document
December 31, 2021 Filed Jan 4, 2022 22:40 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	SaleCommon Stock	17,013	$13.92	$236,756.31	Disclosure SEC source: 0001626199-22-000018 · wf-form4_164133597348174.xml · nonDerivative · entry 1 Rickey James Paul · CIK 0001606243 · Senior VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,014 F1 · price: This transaction was executed in multiple trades at prices ranging from $13.52 to $14.145. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
January 05, 2021 Filed Jan 7, 2021 01:04 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantStock Option (Right to buy) · Derivative	120,000	$0.00 Strike: $13.20	$0.00	Disclosure SEC source: 0001626199-21-000029 · wf-form4_160998142987330.xml · derivative · entry 1 Rickey James Paul · CIK 0001606243 · Senior VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-01-04 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 5, 2021 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document
December 31, 2020 Filed Jan 5, 2021 01:31 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Tax withholdingCommon Stock	2,258	$12.60	$28,450.80	Disclosure SEC source: 0001626199-21-000002 · wf-form4_160981028784324.xml · nonDerivative · entry 1 Rickey James Paul · CIK 0001606243 · Senior VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,027 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document
June 30, 2020 Filed Jul 1, 2020 23:38 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Tax withholdingCommon Stock	2,258	$9.71	$21,925.18	Disclosure SEC source: 0000899243-20-018177 · doc4.xml · nonDerivative · entry 1 Rickey James Paul · CIK 0001606243 · Senior VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,285 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. F2 · balance_after: Certain of these securities are restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each restricted stock unit. Read SEC document
January 23, 2020 Filed Jan 27, 2020 23:02 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantStock Option (right to buy) · Derivative	102,000	$0.00 Strike: $3.23	$0.00	Disclosure SEC source: 0000899243-20-002069 · doc4.xml · derivative · entry 2 Rickey James Paul · CIK 0001606243 · Senior VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,000 Underlying: Common Stock · 102,000 shares Expires 2030-01-22 F2 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document
January 23, 2020 Filed Jan 27, 2020 23:02 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantCommon Stock	18,543	$0.00	$0.00	Disclosure SEC source: 0000899243-20-002069 · doc4.xml · nonDerivative · entry 1 Rickey James Paul · CIK 0001606243 · Senior VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,543 F1 · price: Received a grant of restricted stock units ("RSUs") pursuant to the 2018 Equity Incentive Plan for no consideration. The RSUs were granted in lieu of a portion of cash incentive compensation achieved pursuant to the terms of the Company's Executive Incentive Compensation Plan. Fifty percent (50%) of the RSUs will vest on June 30, 2020 and fifty percent (50%) of the RSUs will vest on December 31, 2020, subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document
May 30, 2019 Filed Jun 3, 2019 12:00 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	PurchaseCommon Stock	10,000	$4.95	$49,500.00	Disclosure SEC source: 0000899243-19-015346 · doc4.xml · nonDerivative · entry 1 Rickey James Paul · CIK 0001606243 · Senior VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.92 to $5.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
February 06, 2019 Filed Feb 8, 2019 21:32 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantStock Option (right to buy) · Derivative	75,000	$0.00 Strike: $6.51	$0.00	Disclosure SEC source: 0000899243-19-003038 · doc4.xml · derivative · entry 1 Rickey James Paul · CIK 0001606243 · Senior VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-02-05 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of February 6, 2019 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document
January 02, 2018 Filed Jan 4, 2018 22:21 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantStock Option (Right to buy) · Derivative	45,000	$0.00 Strike: $11.31	$0.00	Disclosure SEC source: 0000899243-18-000496 · doc4.xml · derivative · entry 1 Rickey James Paul · CIK 0001606243 · Senior VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-01-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 1/4th of the shares subject to the option become vested and exercisable on January 2, 2019 and 1/36th of the remaining shares subject to the option shall vest monthly thereafter. Read SEC document
July 24, 2017 Filed Jul 26, 2017 21:11 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantEmployee Stock Option (right to buy) · Derivative	74,535	$0.00 Strike: $5.02	$0.00	Disclosure SEC source: 0000899243-17-019065 · doc4.xml · derivative · entry 1 Rickey James Paul · CIK 0001606243 · Senior VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,535 Underlying: Common Stock · 74,535 shares Expires 2027-04-11 F1 · derivative.exercise_price: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F2 · derivative.exercise_price: Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. F1 · shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F2 · shares: Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. F3 · derivative.exercise_date: This option vests 25% on April 1, 2018, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions. F1 · derivative.underlying_shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F2 · derivative.underlying_shares: Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.